A Health Economic Evaluation of an Artificial Intelligence-assisted Prescription Review System in a Real-world Setting in China  

作　　者：Di Wu Yingpeng Qiu Liwei Shi Kejun Liu Xueqing Tian Ping Ren Mao You Junrui Pei Wenqi Fu Yue Xiao 

机构地区：[1]Center for Endemic Disease Control,Chinese Center for Disease Control and Prevention,Harbin Medical University,Harbin 150081,Heilongjiang,China [2]Department of Health Economics,School of Health Management,Harbin Medical University,Harbin 150081,Heilongjiang,China [3]China National Health Development Research Center(China National Center for Medicine and Health Technology Assessment),Beijing 100044,China [4]The University of Sheffield,Sheffield S102TN,England,United Kingdom

出　　处：《Biomedical and Environmental Sciences》2025年第3期385-388,共4页生物医学与环境科学(英文版)

基　　金：supported by the Ministry of Science and Technology of the People’s Republic of China under the“New Generation Artificial Intelligence”Major Project of Science and Technology Innovation 2030(2020AAA0105002).

摘　　要：Irrational drug use and prescription safety are pressing global concerns.The World Health Organization estimated that over half of all prescriptions worldwide contain errors,leading to substantial harm[1,2].In China,prescription errors occur at a rate of 32%,and improper medication use is reported in over 70%of households[3,4].Vulnerable populations,including children(16.7%)and older adults(30.4%),are particularly affected[5].

关 键 词：PRESCRIPTION HEALTH ECONOMIC 

分 类 号：F42[经济管理—产业经济]